The Novel Anti-Thrombotic Drug with No-Bleeding Excess-Juniper Publishers
JUNIPER PUBLISHERS - OPEN ACCESS JOURNAL OF CARDIOLOGY & CARDIOVASCULAR THERAPY Abstract Background and purpose: All anti-thrombotic drugs presently available cause increased bleeding, a most undesirable effect. Our aim was to test a novel anti-thrombotic drug [Th001] which, theoretically should not suffer from this disadvantage. Experimental approach: The trial design was a double-blind, placebo controlled, paired crossover, with 99% power for showing a difference in skin bleeding time. n=48 Caucasian patients, age 69.0±6.6 years, 38 male, 10 female, with stable atherothrombotic disease and other stable chronic diseases, treated with aspirin and statin. There was no effect on bleeding time (p =0.9729) nor on tests of haemostasis, (Ultegra point of care aggregation test and flow cytometry). The mean platelet count rose from 234.43±67.264 to 246.43±84.14x10-9 per litre, p=0.024. Conclusion: Th001 therapy appears to be a safe method for potential treatment and preventi